Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep.
Level 5 - mechanism / opinion, no new human data
Preclinical animal laboratory study
PubMed 3496800 · doi:10.1152/ajpregu.1987.253.1.R142
What was done
Researchers tested human recombinant tumor necrosis factor (rTNF) administered via intravenous (IV) or intracerebroventricular (ICV) routes in animals to assess its somnogenic and pyrogenic activity. Responses were compared against human recombinant beta-interleukin 1 (rIL 1), monitoring electroencephalographic (EEG) slow-wave activity, sleep architecture (slow-wave sleep and REM sleep), fevers, and arousal state transitions.
What was found
Administration of rTNF via IV or ICV injection enhanced slow-wave sleep (SWS) and EEG slow-wave activity (0.5-4.0 Hz), suppressed rapid-eye-movement (REM) sleep, and produced biphasic fevers. Recombinant IL-1 caused similar sleep alterations but triggered monophasic fevers. Animal behavior and brain temperature dynamics during state transitions remained intact with both agents. The abstract provides no exact quantitative metrics, sample sizes, or effect estimates beyond the specified EEG frequency band.
Why it matters
This study provides mechanistic evidence that tumor necrosis factor acts alongside interleukin-1 as an endogenous sleep-inducing factor, reinforcing the regulatory link between immune activation and slow-wave sleep.
Limits
The abstract omits the animal species, sample size, control conditions, doses administered, and detailed numerical values or variance. Findings are derived entirely from non-human models and cannot directly establish clinical effects in humans.
Cited by
- supports Injecting pro-inflammatory cytokines into animals induces sleep.